 |
PDBsum entry 1kjh
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.1.-.-
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.1.13.2
- exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 6:
|
 |
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 7:
|
 |
E.C.3.4.23.16
- HIV-1 retropepsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Structure
10:369-381
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes.
|
|
M.Prabu-Jeyabalan,
E.Nalivaika,
C.A.Schiffer.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The homodimeric HIV-1 protease is the target of some of the most effective
antiviral AIDS therapy, as it facilitates viral maturation by cleaving ten
asymmetric and nonhomologous sequences in the Gag and Pol polyproteins. Since
the specificity of this enzyme is not easily determined from the sequences of
these cleavage sites alone, we solved the crystal structures of complexes of an
inactive variant (D25N) of HIV-1 protease with six peptides that correspond to
the natural substrate cleavage sites. When the protease binds to its substrate
and buries nearly 1000 A2 of surface area, the symmetry of the protease is
broken, yet most internal hydrogen bonds and waters are conserved. However, no
substrate side chain hydrogen bond is conserved. Specificity of HIV-1 protease
appears to be determined by an asymmetric shape rather than a particular amino
acid sequence.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
Figure 4.
Figure 4. Conserved Water Structure(A) Fifty-two water
molecules that are conserved in at least four of the five
structures determined to 2.0 Å resolution and form at least two
protein-hydrogen bonds. Those waters found in both monomers are
labeled in bold, and only one of the two is labeled to improve
clarity. Equivalent clusters of waters are colored the same.
Those waters around the substrate peptide are shown in white
(Figure 2). Waters around the P1-loop and the tip of the flap
are shown in yellow.(B) On either side of the P1-loop, the
conserved waters are shown in blue (C) and red (D). Hydrogen
bonds between the protein and water are shown in bold, while
hydrogen bonds between nearby protein atoms are shown in dashed
lines.
|
 |
|
|
|
| |
The above figure is
reprinted
by permission from Cell Press:
Structure
(2002,
10,
369-381)
copyright 2002.
|
|
| |
Figure was
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Engelman,
and
P.Cherepanov
(2012).
The structural biology of HIV-1: mechanistic and therapeutic insights.
|
| |
Nat Rev Microbiol,
10,
279-290.
|
 |
|
|
|
|
 |
H.Ode,
M.Yokoyama,
T.Kanda,
and
H.Sato
(2011).
Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability.
|
| |
J Mol Model,
17,
391-399.
|
 |
|
|
|
|
 |
J.Shibata,
W.Sugiura,
H.Ode,
Y.Iwatani,
H.Sato,
H.Tsang,
M.Matsuda,
N.Hasegawa,
F.Ren,
and
H.Tanaka
(2011).
Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
|
| |
Antiviral Res,
90,
33-41.
|
 |
|
|
|
|
 |
M.K.Singh,
K.Streu,
A.J.McCrone,
and
B.N.Dominy
(2011).
The Evolution of Catalytic Function in the HIV-1 Protease.
|
| |
J Mol Biol,
408,
792-805.
|
 |
|
|
|
|
 |
Z.Liu,
Y.Wang,
J.Brunzelle,
I.A.Kovari,
and
L.C.Kovari
(2011).
Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.
|
| |
Protein J,
30,
173-183.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.N.Nalam,
A.Ali,
M.D.Altman,
G.S.Reddy,
S.Chellappan,
V.Kairys,
A.Ozen,
H.Cao,
M.K.Gilson,
B.Tidor,
T.M.Rana,
and
C.A.Schiffer
(2010).
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.
|
| |
J Virol,
84,
5368-5378.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.K.Sadiq,
and
G.De Fabritiis
(2010).
Explicit solvent dynamics and energetics of HIV-1 protease flap opening and closing.
|
| |
Proteins,
78,
2873-2885.
|
 |
|
|
|
|
 |
A.J.Kandathil,
A.P.Joseph,
R.Kannangai,
N.Srinivasan,
O.C.Abraham,
S.A.Pulimood,
and
G.Sridharan
(2009).
Structural basis of drug resistance by genetic variants of HIV type 1 clade c protease from India.
|
| |
AIDS Res Hum Retroviruses,
25,
511-519.
|
 |
|
|
|
|
 |
M.Kolli,
E.Stawiski,
C.Chappey,
and
C.A.Schiffer
(2009).
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
|
| |
J Virol,
83,
11027-11042.
|
 |
|
|
|
|
 |
P.M.Colman
(2009).
New antivirals and drug resistance.
|
| |
Annu Rev Biochem,
78,
95.
|
 |
|
|
|
|
 |
R.N.Jorissen,
G.S.Reddy,
A.Ali,
M.D.Altman,
S.Chellappan,
S.G.Anjum,
B.Tidor,
C.A.Schiffer,
T.M.Rana,
and
M.K.Gilson
(2009).
Additivity in the analysis and design of HIV protease inhibitors.
|
| |
J Med Chem,
52,
737-754.
|
 |
|
|
|
|
 |
R.S.Saksena,
B.Boghosian,
L.Fazendeiro,
O.A.Kenway,
S.Manos,
M.D.Mazzeo,
S.K.Sadiq,
J.L.Suter,
D.Wright,
and
P.V.Coveney
(2009).
Real science at the petascale.
|
| |
Philos Transact A Math Phys Eng Sci,
367,
2557-2571.
|
 |
|
|
|
|
 |
S.Bihani,
A.Das,
V.Prashar,
J.L.Ferrer,
and
M.V.Hosur
(2009).
X-ray structure of HIV-1 protease in situ product complex.
|
| |
Proteins,
74,
594-602.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Chaudhury,
and
J.J.Gray
(2009).
Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance.
|
| |
Structure,
17,
1636-1648.
|
 |
|
|
|
|
 |
V.Prashar,
S.Bihani,
A.Das,
J.L.Ferrer,
and
M.Hosur
(2009).
Catalytic water co-existing with a product peptide in the active site of HIV-1 protease revealed by X-ray structure analysis.
|
| |
PLoS One,
4,
e7860.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.J.Illingworth,
K.E.Parkes,
C.R.Snell,
and
C.A.Reynolds
(2008).
Quantitative measurement of protease ligand conformation.
|
| |
J Comput Aided Mol Des,
22,
105-109.
|
 |
|
|
|
|
 |
E.Lefebvre,
and
C.A.Schiffer
(2008).
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
|
| |
AIDS Rev,
10,
131-142.
|
 |
|
|
|
|
 |
H.Eizert,
P.Bander,
P.Bagossi,
T.Sperka,
G.Miklóssy,
P.Boross,
I.T.Weber,
and
J.Tözsér
(2008).
Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.
|
| |
J Virol,
82,
10111-10117.
|
 |
|
|
|
|
 |
J.Kóna
(2008).
Theoretical study on the mechanism of a ring-opening reaction of oxirane by the active-site aspartic dyad of HIV-1 protease.
|
| |
Org Biomol Chem,
6,
359-365.
|
 |
|
|
|
|
 |
M.D.Altman,
E.A.Nalivaika,
M.Prabu-Jeyabalan,
C.A.Schiffer,
and
B.Tidor
(2008).
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease.
|
| |
Proteins,
70,
678-694.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.J.Giffin,
H.Heaslet,
A.Brik,
Y.C.Lin,
G.Cauvi,
C.H.Wong,
D.E.McRee,
J.H.Elder,
C.D.Stout,
and
B.E.Torbett
(2008).
A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant.
|
| |
J Med Chem,
51,
6263-6270.
|
 |
|
|
|
|
 |
M.N.Nalam,
and
C.A.Schiffer
(2008).
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors.
|
| |
Curr Opin HIV AIDS,
3,
642-646.
|
 |
|
|
|
|
 |
T.Hou,
W.A.McLaughlin,
and
W.Wang
(2008).
Evaluating the potency of HIV-1 protease drugs to combat resistance.
|
| |
Proteins,
71,
1163-1174.
|
 |
|
|
|
|
 |
A.Y.Kovalevsky,
A.A.Chumanevich,
F.Liu,
J.M.Louis,
and
I.T.Weber
(2007).
Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate.
|
| |
Biochemistry,
46,
14854-14864.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.Z.Liang,
and
S.Z.Li
(2007).
A new sequence representation as applied in better specificity elucidation for human immunodeficiency virus type 1 protease.
|
| |
Biopolymers,
88,
401-412.
|
 |
|
|
|
|
 |
H.Heaslet,
R.Rosenfeld,
M.Giffin,
Y.C.Lin,
K.Tam,
B.E.Torbett,
J.H.Elder,
D.E.McRee,
and
C.D.Stout
(2007).
Conformational flexibility in the flap domains of ligand-free HIV protease.
|
| |
Acta Crystallogr D Biol Crystallogr,
63,
866-875.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Heaslet,
Y.C.Lin,
K.Tam,
B.E.Torbett,
J.H.Elder,
and
C.D.Stout
(2007).
Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
|
| |
Retrovirology,
4,
1.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.E.Foulkes-Murzycki,
W.R.Scott,
and
C.A.Schiffer
(2007).
Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease.
|
| |
Structure,
15,
225-233.
|
 |
|
|
|
|
 |
M.N.Nalam,
A.Peeters,
T.H.Jonckers,
I.Dierynck,
and
C.A.Schiffer
(2007).
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease.
|
| |
J Virol,
81,
9512-9518.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Prabu-Jeyabalan,
E.A.Nalivaika,
K.Romano,
and
C.A.Schiffer
(2006).
Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.
|
| |
J Virol,
80,
3607-3616.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Prabu-Jeyabalan,
N.M.King,
E.A.Nalivaika,
G.Heilek-Snyder,
N.Cammack,
and
C.A.Schiffer
(2006).
Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease.
|
| |
Antimicrob Agents Chemother,
50,
1518-1521.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Ozer,
T.Haliloglu,
and
C.A.Schiffer
(2006).
Substrate specificity in HIV-1 protease by a biased sequence search method.
|
| |
Proteins,
64,
444-456.
|
 |
|
|
|
|
 |
T.L.O'Loughlin,
D.N.Greene,
and
I.Matsumura
(2006).
Diversification and specialization of HIV protease function during in vitro evolution.
|
| |
Mol Biol Evol,
23,
764-772.
|
 |
|
|
|
|
 |
L.You,
D.Garwicz,
and
T.Rögnvaldsson
(2005).
Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease.
|
| |
J Virol,
79,
12477-12486.
|
 |
|
|
|
|
 |
M.L.Geddie,
T.L.O'Loughlin,
K.K.Woods,
and
I.Matsumura
(2005).
Rational design of p53, an intrinsically unstructured protein, for the fabrication of novel molecular sensors.
|
| |
J Biol Chem,
280,
35641-35646.
|
 |
|
|
|
|
 |
P.Bagossi,
T.Sperka,
A.Fehér,
J.Kádas,
G.Zahuczky,
G.Miklóssy,
P.Boross,
and
J.Tözsér
(2005).
Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.
|
| |
J Virol,
79,
4213-4218.
|
 |
|
|
|
|
 |
P.Martin,
J.F.Vickrey,
G.Proteasa,
Y.L.Jimenez,
Z.Wawrzak,
M.A.Winters,
T.C.Merigan,
and
L.C.Kovari
(2005).
"Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.
|
| |
Structure,
13,
1887-1895.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Tie,
P.I.Boross,
Y.F.Wang,
L.Gaddis,
F.Liu,
X.Chen,
J.Tozser,
R.W.Harrison,
and
I.T.Weber
(2005).
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
|
| |
FEBS J,
272,
5265-5277.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Johnston,
M.A.Winters,
S.Y.Rhee,
T.C.Merigan,
C.A.Schiffer,
and
R.W.Shafer
(2004).
Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.
|
| |
Antimicrob Agents Chemother,
48,
4864-4868.
|
 |
|
|
|
|
 |
M.Prabu-Jeyabalan,
E.A.Nalivaika,
N.M.King,
and
C.A.Schiffer
(2004).
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.
|
| |
J Virol,
78,
12446-12454.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.M.King,
M.Prabu-Jeyabalan,
E.A.Nalivaika,
and
C.A.Schiffer
(2004).
Combating susceptibility to drug resistance: lessons from HIV-1 protease.
|
| |
Chem Biol,
11,
1333-1338.
|
 |
|
|
|
|
 |
N.M.King,
M.Prabu-Jeyabalan,
E.A.Nalivaika,
P.Wigerinck,
M.P.de Béthune,
and
C.A.Schiffer
(2004).
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.
|
| |
J Virol,
78,
12012-12021.
|
 |
|
|
|
|
 |
S.Tuske,
S.G.Sarafianos,
A.D.Clark,
J.Ding,
L.K.Naeger,
K.L.White,
M.D.Miller,
C.S.Gibbs,
P.L.Boyer,
P.Clark,
G.Wang,
B.L.Gaffney,
R.A.Jones,
D.M.Jerina,
S.H.Hughes,
and
E.Arnold
(2004).
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.
|
| |
Nat Struct Mol Biol,
11,
469-474.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Katoh,
J.M.Louis,
T.Yamazaki,
A.M.Gronenborn,
D.A.Torchia,
and
R.Ishima
(2003).
A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex.
|
| |
Protein Sci,
12,
1376-1385.
|
 |
|
|
|
|
 |
M.Prabu-Jeyabalan,
E.A.Nalivaika,
N.M.King,
and
C.A.Schiffer
(2003).
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy.
|
| |
J Virol,
77,
1306-1315.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.Kurt,
T.Haliloglu,
and
C.A.Schiffer
(2003).
Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease.
|
| |
Biophys J,
85,
853-863.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |